Brief: Enanta Pharmaceuticals Initiates Phase 2 Trial Of Its Covid-19 Treatment
09/11/2022 12:30
Nov 9 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS INITIATES SPRINT, A PHASE 2
CLINICAL
TRIAL OF EDP-235, ITS ORAL, DIRECT-ACTING ANTIVIRAL PROTEASE
INHIBITOR SPECIFICALLY DESIGNED FOR THE TREATMENT OF COVID-19
Source text for Eikon: ID:nBw5Dg0qna
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates